Late effects after chemotherapy;Folgeerkrankungen nach chemotherapie

Internist

Volumn 47, Issue 3, 2006, Pages 266-273

  Ponisch W ^a   Niederwieser, D ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Cancer; Cardiotoxicity; Chemotherapy; Late effects; Secondary Malignancies

Indexed keywords

ALKYLATING AGENT; AMSACRINE; ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; LOMUSTINE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PACLITAXEL; PARACETAMOL; PLATINUM DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VINCA ALKALOID;

ARTICLE; AUTONOMIC NEUROPATHY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CONSTIPATION; DRUG DOSE REDUCTION; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; HYPOTENSION; ILEUS; IMMUNE DEFICIENCY; IMPOTENCE; LIVER TOXICITY; LUNG FIBROSIS; LUNG TOXICITY; METASTASIS; MORTALITY; MYOCARDITIS; NEPHROTOXICITY; NEUROTOXICITY; PARESTHESIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PNEUMONIA; PROGNOSIS; SOLID TUMOR; SPLENECTOMY; SURVIVAL TIME;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOMYOPATHIES; CHILD; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; HEPATITIS, TOXIC; HUMANS; LUNG DISEASES, INTERSTITIAL; NEOPLASMS; NEPHRITIS, INTERSTITIAL; NERVOUS SYSTEM DISEASES; PULMONARY FIBROSIS; RISK FACTORS; SURVIVAL RATE;

EID: 33645318170     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-006-1577-z     Document Type: Article

References (21)

1. Ades L, Guardiola P, Socie G (2002) Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems. Blood Rev 16: 135-146
2. + lymphocytopenia after treatment. Leuk Lymphoma 35: 555-565
3. Bonadonna G, Viviani S, Bonfante V et al. (2005) Survival in Hodgkin's disease patients - report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer 41: 998-1006
4. Brown JR, Yeckes H, Friedberg JW et al. (2005) Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 23: 2208-2214
5. Eigen H, Wyszomierski D (1985) Bleomycin lung injury in children: pathophysiology and guidlines for management. Am J Pediatr Hematol Oncol 7: 71-79
6. Franchini M, Gandini G, Veneri D et al. (2004) Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia. Transfusion 44: 833-837
7. Lipshultz SE, Sallan SE (1993) Cardiovascular abnormalities in long-term survivors of childhood malignancy. J Clin Oncol 11: 1199-1203
8. Lipshultz SE, Rifai N, Dalton VM et al. (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351: 145-153
9. Locasciulli A, Testa M, Valsecchi MG et al. (1999) The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation 68: 1486-1491
10. McKeage K, Perry CM (2002) Trastuzumab. Drugs 62: 209-243
11. Metayer C, Curtis RE, Vose J et al. (2003) Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 101: 2015-2023
12. Nichols CR, Breeden ES, Loehrer PJ et al. (1993) Secondary leukemia associated with a conventional dose of etoposide. J Natl Cancer Inst 85: 36-40
13. Ng AK, Bernardo MV, Weller E et al. (2002) Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100: 1989-1996
14. Pihkala J, Saarinen UM, Lundstrom U et al. (1996) Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 32A: 97-103
15. Schmid P, Possinger K (2001) Liposomal anthracyclinefor improved cardiac tolerability. Breast 10 [Suppl 2]: 22-27
16. Shapiro CL, Hardenbergh PH, Gelman R et al. (1998) Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 16: 3493-3501
17. Smith SM, Le Beau MM, Huo D et al. (2003) Clincal-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102: 43-52
18. Stewart JR, Fajardo LF, Gillette SM et al. (1995) Radiation injury to the heart. Int J Radiat Oncol Biol Phys 31: 1205-1211
19. Swain SM, Whaley FS, Ever MS (2003) Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97: 2869-2879
20. Veinot JP, Edwards WD (1996) Pathology of radiation-induced heart disease: A surgical and autopsy study of 27 cases. Hum Pathol 27: 766-773
21. Von Hoff DD, Layard MW, Basa P et al. (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 91: 710-717